The Effect of Viscous Dietary Fibers on LDL-cholesterol

NCT04133805 | Unknown

• 1 other identifier: Viscous fiber on LDL-C
• Study Type: observational
• Target: 7,845
• Locations: 1 country
• Sites: 1

Brief Summary

This systematic review and meta-analysis is aimed to assess the effect of commonly consumed viscous fibers on blood lipids including LDL-C, non-HDL-C, and ApoB.

Conditions

Cardiovascular Risk Factor; Hypercholesterolemia

Keywords

viscous fiber; barley b-glucan; oat b-glucan; konjac glucomannan; psyllium; guar gum; pectin

Outcome Measures

Primary Outcomes (1)

• LDL-Cholesterol

  ≥ 3 weeks

Secondary Outcomes (2)

• non-HDL-Cholesterol

  ≥ 3 weeks

• ApoB

  ≥ 3 weeks

Interventions

viscous fiber DIETARY_SUPPLEMENT

ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Hypercholesterolemic or normocholesterolemic adults, overweight and obese individuals or individuals with diabetes

You may qualify if:

• Must be a randomized controlled clinical trial with either a parallel or cross-over design
• have a treatment period of at least 3 weeks
• Hypercholesterolemic or normocholesterolemic adults, overweight and obese individuals or individuals with diabetes were all acceptable
• Sources from β-glucan oats, β-glucan barley, konjac, psyllium, guar gum, and pectin were accepted
• The amount of soluble fiber must be reported or measured or must be computable.
• Must be appropriately controlled.
• Must measure one of LDL-C, non-HDL-C or ApoB. These lipid measures can be either primary or secondary outcomes.
• Enough information must be provided to calculate the magnitude of effect, i.e. end of treatment measures and/or change from baseline measures

You may not qualify if:

• If the study was insufficiently controlled, i.e. the control was another soluble fiber
• If the soluble fiber was a combination supplement or in whole food sources where the amount of soluble fiber could not be isolated
• If the outcome measures did not include LDL-C, non-HDL-C or ApoB
• If the treatment period was less than 3 weeks
• If the study was from a non-adult population
• If the study provided insufficient information to calculate a magnitude of effect
• Secondary information such as reviews, editorials, commentaries, were excluded
• If the dose was less than 0.4g/day

Sponsors & Collaborators

• Unity Health Toronto: lead

Study Sites (1)

Clinical Risk Factor and Modification Centre

Toronto, Ontario, M5C 2T2, Canada

Location

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2019
• First Posted: October 21, 2019
• Study Start: September 17, 2018
• Primary Completion: December 1, 2019
• Study Completion: January 1, 2020
• Last Updated: October 21, 2019

Record last verified: 2019-10

Locations

CA (1)